In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Madrigal nets $282.7mm via FOPO

Executive Summary

Madrigal Pharmaceuticals Inc. (developing therapies for cardiovascular, metabolic, and liver diseases) netted $282.7mm through the follow-on public offering of 983,607 common shares at $305 each. Stockholders sold an additional 363,625 shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies